<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021579</url>
  </required_header>
  <id_info>
    <org_study_id>SUMS 84-258</org_study_id>
    <nct_id>NCT01021579</nct_id>
  </id_info>
  <brief_title>Effects of Metformin Plus Simvastatin on Polycystic Ovarian Syndrome (PCOS): A Prospective, Randomized, Double-Blind, Placebo-Controlled Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fasa University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shiraz University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fasa University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting 6.5%-6.7% of women in&#xD;
      reproductive age, and is commonly associated with obesity, menstrual irregularity, insulin&#xD;
      resistance (IR), infertility, and clinical hyperandrogenism and/or hyperandrogenemia (1,2).&#xD;
      PCOS is also associated with increased risk of abnormal lipoproteins and hypertension, as&#xD;
      well as cardiovascular or cerebrovascular morbidity (3). The lipid and lipoprotein profile in&#xD;
      androgenized women with poly cystic ovaries is similar to the made pattern with higher levels&#xD;
      of cholesterol, low-density lipoprotein (LDL), and lower levels of high-density lipoprotein&#xD;
      (HDL), and this abnormal pattern is independent of body weight (4). Insulin resistance is&#xD;
      associated with reproductive abnormalities in women with PCOS. Improving insulin sensitivity&#xD;
      through both lifestyle and pharmacological intervention can ameliorate these abnormalities.&#xD;
      Insulin resistance in women with PCOS is common (up to 50%), both in obese and nonobese women&#xD;
      (5), and disordered insulin action precedes the increase in androgen.&#xD;
&#xD;
      Treatment for PCOS subjects typically includes, implementation of lifestyle changes&#xD;
      especially weight loss and adjuvant pharmaceutical intervention including oral&#xD;
      contraceptives, anti-androgen therapy and insulin-lowering drugs (such as, metformin) (6).&#xD;
      Metformin is a biguanide used extensively in type 2 diabetes. It inhibits hepatic glucose&#xD;
      production and increases peripheral insulin sensitivity, but dose not cause hypoglycemia.&#xD;
      Several studies have shown an increase in insulin sensitivity and pregnancy rate accompanied&#xD;
      by decreased insulin and androgen levels in PCOS patients taking metformin (7).&#xD;
&#xD;
      The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-COA) reductase inhibitors (statins) are the&#xD;
      rate-limiting step in cholesterol biosynthesis, and inhibition of this enzyme decreases&#xD;
      cholesterol synthesis and a compensatory increase in the expression of LDL receptors in the&#xD;
      liver. Statins reduce plasma triglycerides in dose-dependent fashion and also have a modest&#xD;
      HDL-raising effect which is not dose-dependent (8,9). Furthermore, statins pose other&#xD;
      cardio-protective properties, including antioxidant and anti-inflammatory actions (10,11).&#xD;
&#xD;
      Some studies have reported that simvastatin decreases serum androgen levels in women with&#xD;
      PCOS (12,13) by inhibiting proliferation and steroidogenesis of ovarian theca-interstitial&#xD;
      cells (14). According to these previous findings, we hypothesized that combination therapy&#xD;
      with simvastatin and metformin will result in lower androgen levels and cardiovascular risk&#xD;
      factors in women with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum total testosterone</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid profile BMI (kg/m2) Total Chol. (mg/dl) HDL (mg/dl) LDL (mg/dl) TG (mg/dl) Testosterone (ng/ml) LH (mIU/ml) FSH (mIU/ml) LH/FSH DHEAS (microgr/dL) Hirsutism score Prolactin (ng/dL) FBS (mg/dL) Fasting Insulin (Î¼U/ml) QUICKI index</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin plus Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PCOS patients(n=42) will be assigned to the simvastatin (20mg/day) plus metformin (500mg three times a day, n=42; group 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin plus Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin plus Placebo</intervention_name>
    <description>PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)</description>
    <arm_group_label>Metformin plus Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metfomin plus Simvastatin</intervention_name>
    <arm_group_label>Metformin plus Simvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients should have at least two of three following criteria: I) chronic&#xD;
             anovulation, II) clinical and/or biochemical evidence of androgen excess and III)&#xD;
             polycystic-appearing ovaries on transvaginal ultrasound.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with Cushing's syndrome, hyperprolactinemia, diabetes mellitus (DM), thyroid&#xD;
             disease, adrenal hyperplasia and androgen-secreting tumors or other endocrinopathies,&#xD;
             will be excluded from the study.&#xD;
&#xD;
          -  Patients with adrenal hyperplasia will be excluded by ACTH-stimulated&#xD;
             17-hydroxyprogesterone levels less than 10 ng/ml (15), and ACTH-stimulated&#xD;
             11-deoxycortisol levels less than 21 ng/ml [3-fold the 95th percentile (16) of a&#xD;
             historical control group of 60 healthy women controls].&#xD;
&#xD;
          -  Those subjects who have kidney or liver diseases and those who were smoker or had&#xD;
             breast cancer will also be excluded from the study.&#xD;
&#xD;
          -  None of the participants receive oral contraceptives (OCPs), steroid hormones or any&#xD;
             medications that interfere with lipid metabolism, ovarian and pituitary and&#xD;
             hypothalamic function, or insulin sensitivity in the last 3 months before study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zainabieh Hospital</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <zip>7173646199</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2009</verification_date>
  <study_first_submitted>November 23, 2009</study_first_submitted>
  <study_first_submitted_qc>November 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2009</study_first_posted>
  <last_update_submitted>November 27, 2009</last_update_submitted>
  <last_update_submitted_qc>November 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2009</last_update_posted>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>Metformin</keyword>
  <keyword>Simvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

